Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals Inc (NQ: CTXR )

0.5596 +0.0096 (+1.75%)
Streaming Delayed Price Updated: 12:16 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 643,045
Open 0.5700
Bid (Size) 0.5502 (25)
Ask (Size) 0.5559 (12)
Prev. Close 0.5500
Today's Range 0.5409 - 0.5769
52wk Range 0.4800 - 1.070
Shares Outstanding 145,979,429
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024
CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-30.80%
-30.80%
1 Month
-7.24%
-7.24%
3 Month
-12.63%
-12.63%
6 Month
-25.42%
-25.42%
1 Year
-19.56%
-19.56%

More News

Read More
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology
Via News Direct
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products
Via News Direct
This Pharma Company Is Preparing To Launch Its Lead Candidate
Via News Direct
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Via Newsfile
Exposures Product Safety
Analysts Hunt for Undervalued Biotech Stocks
Via Newsfile
Topics Economy Initial Public Offering
Exposures Interest Rates Securities Market
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
Via AB Newswire
Bloodstream Infections - From Threats to Solutions
Via Newsfile
Topics Death
Exposures Death
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
Via AB Newswire
Exposures Product Safety
Biopharma Stocks Transformative Innovation for the Future of Health
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections
Via Benzinga
Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue
Via InvestorPlace
Topics Product Recall
Exposures Legal Product Safety
VFS Stock Alert: VinFast Plunges on NHTSA Probe
Via InvestorPlace
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Exposures Product Safety
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
Via InvestorPlace
Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment
Via News Direct
Topics Death
Exposures Death
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Via Benzinga
Why Citius Pharmaceuticals Stock Is Plunging Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.